# A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

> **NCT02609230** · PHASE1 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Advanced Solid Tumors
- Multiple Myeloma

## Interventions

- **DRUG:** ONC-201

## Key facts

- **NCT ID:** NCT02609230
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-05
- **Primary completion:** 2020-03
- **Final completion:** 2020-03-26
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609230, "A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02609230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*